Learn About Benlysta

benlysta

 When the FDA approved Benlysta to treat lupus it became the first new lupus drug approved in 56 years.

Prior to Benlysta, the FDA last approved drugs to treat lupus in 1955, Plaquenil (hydrozychloroquine) and corticosteriods. Aspirin was approved to treat lupus in 1948.

The Lupus Alliance of LIQ  has designed this page to help you find out what you need to know about Benlysta. From safety information to the full prescribing information and medical guide, you will find the information you need here.

Benlysta Co-Pay Assistance Program

In response to the worry by many that they will not be able to afford Benlsyta, Glaxo SmithKline has come out with Benlysta Gateway as a way to help pay for co-pays. Hopefully this will be the first in a long line of financial assistance programs to help those with lupus pay for this new medication.
To visit the Benlysta Gateway Co-Pay Assistance Website, please click here.

About Benlysta

BENLYSTA (belimumab)

Is the first in a new class of drugs called BLyS-specific inhibitors. Belimumab blocks the binding of soluble BLyS, a B-cell survival factor, to its receptors on B cells. Belimumab does not bind B cells directly, but by binding BLyS, belimumab inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.BLyS is a naturally occurring protein which was discovered by HGS in 1996. BENLYSTA is made available as a lyophilized powder in single-use vials for intravenous infusion only and must be reconstituted and diluted by a healthcare professional prior to administration.

GSK submitted a Marketing Authorization Application (MAA) for BENLYSTA to the European Medicines Agency (EMA) in June 2010. Regulatory applications have also been submitted and are currently under consideration in Canada, Australia, Switzerland, Russia, Brazil and The Philippines.

How BENLYSTA Works

Belimumab blocks the binding of soluble BLyS, a B-cell survival factor, to its receptors on B cells. Belimumab does not bind B cells directly, but by binding BLyS, belimumab inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. BLyS is a naturally occurring protein which was discovered by HGS in 1996.

What are the ingredients in BENLYSTA?

Active ingredient: belimumab.

Inactive ingredients: citric acid, polysorbate 80, sodium citrate, sucrose.